An inhibitor of cell metabolism may be a good therapeutic target for neuroblastoma, which accounts for about 15 percent of pediatric cancer-related deaths.
A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target.
Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks.